DuraHeart (TM) Magnetically Levitated Left Ventricular Assist Device - Osaka University Experience -

作者：Sakaguchi Taichi; Matsumiya Goro; Yoshioka Daisuke; Miyagawa Shigeru; Nishi Hiroyuki; Yoshikawa Yasushi; Fukushima Satsuki; Saito Shunsuke; Ueno Takayoshi; Sawa Yoshiki^*

来源：Circulation Journal, 2013, 77(7): 1736-1741.

DOI：10.1253/circj.CJ-12-1410

• Cardiomyopathy
• Heart failure
• Transplantation
• Ventricular assist device

Background: The DuraHeart left ventricular assist device (LVAD) is the world%26apos;s first approved magnetically levitated implantable centrifugal pump. We report our initial experience with the DuraHeart as a bridge to heart transplantation. %26lt;br%26gt;Methods and Results: Between 2008 and 2011,23 patients (17 males; mean age 35 years, range 16-53 years) with endstage heart failure underwent implantation with the DuraHeart LVAD at Osaka University Hospital. Of those, 7 underwent conversion surgery from a Nipro paracorporeal LVAD to the DuraHeart. There were no deaths during the mean support period of 559 +/- 241 days (176-999 days). In total, 17 patients (74%) remain with the LVAD and 5 (22%) underwent heart transplantation after 580 +/- 302 days (176-982 days) of support. Major adverse events included 8(34%) driveline/pocket infections, 4(17%) cerebrovascular accidents, 4(17%) right heart failures requiring mechanical support, and 3 (13%) mechanical device failures (magnetic levitation failure caused by driveline fracture). Of the 5 patients who developed pump pocket infection, 3 underwent previous conversion surgery from the Nipro LVAD. %26lt;br%26gt;Conclusions: Our initial experience with the DuraHeart LVAD in Japan demonstrated excellent long-term survival with acceptable rates of adverse events. With refinement of the system, including mechanical durability, this pump will further enhance the quality of life for patients who require long-term mechanical circulatory support.

• 出版日期2013-7